StockTipsArenaBeta

BUY Piramal Pharma Limited — Amol Athawale, Kotak Securities

BUYPiramal Pharma Limited
Piramal Pharma share price target & all analyst calls

byAmol Athawale, Kotak SecuritiesHorizon: 1–3 months4 Nov 2026via Zee Business (Live)

Entry₹236.8Inferred
Target₹270
Total upside +14.02%
Stop loss₹220-7.09% risk
CMP₹239.321d ago
Active+1.06%+12.82%upside left 3 mo left
Follow Amol Athawale for new calls(30% target hit, 30 closed calls)Get alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 1 other Short-term call on PPLPHARMASee 73 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:23 pm IST
11 supporting1 neutral1 opposing
Supports the BUY call (11)

MACD above its signal line — bullish momentum

Technicals · macd·7 Nov · today

Past month's volume 2.6× the prior month's average

Technicals · volume·6 Nov · yesterday

9 advisors have active long-term BUY calls on this stock, with 7 issued in the last 14 days

Advisor consensus · adjacent horizon·6 Nov · yesterday

Piramal Pharma shares surge 17% as Q2 revenue rises 28.1% YoY to ₹2,617 Cr and net profit turns positive to ₹5.6 Cr

NewsGoogle News·28 Oct · 1w ago

(opens in new tab)

Telecom could become one of Nifty’s biggest sectors after financials, says ICICI Securities

NewsCnbc-Tv18·28 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (1)

Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·27 Oct · 1w ago

(opens in new tab)
Weighs against the BUY call (1)

RSI at 76 — overbought territory

Technicals · rsi·7 Nov · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Piramal Pharma

All analyst calls on Piramal Pharma

More from Amol Athawale, Kotak Securities

Every call and its outcome